Comparing Genomic Variation Patterns in Blood and Tumor Tissue in Patients with Triple Negative Breast Cancer - COGENT

Department of Science and Technology Government of India0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年4月4日

试验速览

暂无简介。

•Inclusion Criteria:
•1.Signed and written informed consent approved by the Ethical Review Board.
•2.Age 18+ years
•3.ER & PR-negative tumor defined by at least one of the following:
•a.ER < 1% and PR <1% positive cells by IHC
•4.HER2-normal tumor defined by at least one of the following:
•a.HER2 0 or 1+ by immunohistochemistry
•b.HER2 2+ by IHC and HER2 to centromere 17 ratios < 2.0 and/or less than 6 copies by in situ hybridization (ISH).
•5.Consent for germline mutation screening for BRCA1, BRCA2, and other inherited breast cancer-associated genes.

•Exclusion Criteria:
•1.On previous therapy such as chemotherapy, radiation, surgery, inhibitor therapy, etc.
•2.A patient who is either pregnant or actively breastfeeding.
•3.Has comorbidities that might hinder the study or its processes. Including severe cardiovascular disorders, haematological disorders, chronic neurological or renal disorders, inadequate organ function, inflammatory or infectious diseases, etc.
•4.Allergy to any of the procedures involved in the study.
•5.Unable to tolerate the position or procedure needed to be undergone during the study.

发起方

Department of Science and Technology Government of India